FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3192409202> ?p ?o ?g. }

• W3192409202 endingPage "e344" @default.
• W3192409202 startingPage "e343" @default.
• W3192409202 abstract "Mengqian Li concluded that in our study, 1 Pires da Silva I Ahmed T Reijers ILM et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021; 22: 836-847 Summary Full Text Full Text PDF Scopus (17) Google Scholar the effect of Eastern Cooperative Oncology Group (ECOG) performance status on clinical outcomes was not elaborated on, nor was the better baseline ECOG performance status in the ipilimumab plus anti-PD-1 combination group compared with the monotherapy group made clear. However, we did a multivariable analysis adjusting for potential confounders and differences in baseline characteristics, as is standard for retrospective analyses of this kind. A specific exploratory analysis of the independent effect of important baseline factors would not provide additional insights, particularly given the well known weaknesses and biases of a retrospective study. In fact, such exploratory analyses were removed in the editorial process. Furthermore, we did a subgroup analysis (including ECOG performance status and other important prognostic factors) and made the differences in each treatment group clear in the reporting of the results. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort studyIn patients who are resistant to anti-PD-(L)1, ipilimumab plus anti-PD-1 seemed to yield higher efficacy than ipilimumab with a higher objective response rate, longer progression-free, and longer overall survival, with a similar rate of grade 3–5 toxicity. Ipilimumab plus anti-PD-1 should be favoured over ipilimumab alone as a second-line immunotherapy for these patients with advanced melanoma. Full-Text PDF Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanomaThe multivariable analysis by Ines Pires da Silva and colleagues1 in The Lancet Oncology showed that in patients with anti-PD-(L)1-resistant metastatic melanoma, treatment with a combination of ipilimumab plus anti-PD-1 was associated with a significantly higher objective response rate and significantly longer overall survival than ipilimumab monotherapy, and that an Eastern Cooperative Oncology Group (ECOG) performance status of 0 was also associated with longer overall survival. Full-Text PDF" @default.
• W3192409202 created "2021-08-16" @default.
• W3192409202 creator A5009968141 @default.
• W3192409202 creator A5013399740 @default.
• W3192409202 creator A5017778536 @default.
• W3192409202 creator A5022520811 @default.
• W3192409202 creator A5022668182 @default.
• W3192409202 creator A5025067315 @default.
• W3192409202 creator A5025478490 @default.
• W3192409202 creator A5029398339 @default.
• W3192409202 creator A5036987287 @default.
• W3192409202 creator A5038759671 @default.
• W3192409202 creator A5040969461 @default.
• W3192409202 creator A5050031536 @default.
• W3192409202 creator A5052403208 @default.
• W3192409202 creator A5059961435 @default.
• W3192409202 creator A5064026461 @default.
• W3192409202 creator A5064923908 @default.
• W3192409202 creator A5065819179 @default.
• W3192409202 creator A5069095893 @default.
• W3192409202 creator A5070576000 @default.
• W3192409202 creator A5071144743 @default.
• W3192409202 creator A5082278497 @default.
• W3192409202 creator A5083061830 @default.
• W3192409202 creator A5090545021 @default.
• W3192409202 date "2021-08-01" @default.
• W3192409202 modified "2023-10-17" @default.
• W3192409202 title "Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply" @default.
• W3192409202 cites W1904369736 @default.
• W3192409202 cites W2151180605 @default.
• W3192409202 cites W2551317550 @default.
• W3192409202 cites W2885140428 @default.
• W3192409202 cites W3043703771 @default.
• W3192409202 cites W3163284774 @default.
• W3192409202 doi "https://doi.org/10.1016/s1470-2045(21)00419-8" @default.
• W3192409202 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34339647" @default.
• W3192409202 hasPublicationYear "2021" @default.
• W3192409202 type Work @default.
• W3192409202 sameAs 3192409202 @default.
• W3192409202 citedByCount "2" @default.
• W3192409202 countsByYear W31924092022022 @default.
• W3192409202 countsByYear W31924092022023 @default.
• W3192409202 crossrefType "journal-article" @default.
• W3192409202 hasAuthorship W3192409202A5009968141 @default.
• W3192409202 hasAuthorship W3192409202A5013399740 @default.
• W3192409202 hasAuthorship W3192409202A5017778536 @default.
• W3192409202 hasAuthorship W3192409202A5022520811 @default.
• W3192409202 hasAuthorship W3192409202A5022668182 @default.
• W3192409202 hasAuthorship W3192409202A5025067315 @default.
• W3192409202 hasAuthorship W3192409202A5025478490 @default.
• W3192409202 hasAuthorship W3192409202A5029398339 @default.
• W3192409202 hasAuthorship W3192409202A5036987287 @default.
• W3192409202 hasAuthorship W3192409202A5038759671 @default.
• W3192409202 hasAuthorship W3192409202A5040969461 @default.
• W3192409202 hasAuthorship W3192409202A5050031536 @default.
• W3192409202 hasAuthorship W3192409202A5052403208 @default.
• W3192409202 hasAuthorship W3192409202A5059961435 @default.
• W3192409202 hasAuthorship W3192409202A5064026461 @default.
• W3192409202 hasAuthorship W3192409202A5064923908 @default.
• W3192409202 hasAuthorship W3192409202A5065819179 @default.
• W3192409202 hasAuthorship W3192409202A5069095893 @default.
• W3192409202 hasAuthorship W3192409202A5070576000 @default.
• W3192409202 hasAuthorship W3192409202A5071144743 @default.
• W3192409202 hasAuthorship W3192409202A5082278497 @default.
• W3192409202 hasAuthorship W3192409202A5083061830 @default.
• W3192409202 hasAuthorship W3192409202A5090545021 @default.
• W3192409202 hasConcept C121608353 @default.
• W3192409202 hasConcept C126322002 @default.
• W3192409202 hasConcept C143998085 @default.
• W3192409202 hasConcept C167135981 @default.
• W3192409202 hasConcept C2776999253 @default.
• W3192409202 hasConcept C2777658100 @default.
• W3192409202 hasConcept C2777701055 @default.
• W3192409202 hasConcept C2778715236 @default.
• W3192409202 hasConcept C2781433595 @default.
• W3192409202 hasConcept C2994587330 @default.
• W3192409202 hasConcept C502942594 @default.
• W3192409202 hasConcept C535046627 @default.
• W3192409202 hasConcept C71924100 @default.
• W3192409202 hasConcept C72563966 @default.
• W3192409202 hasConcept C77350462 @default.
• W3192409202 hasConceptScore W3192409202C121608353 @default.
• W3192409202 hasConceptScore W3192409202C126322002 @default.
• W3192409202 hasConceptScore W3192409202C143998085 @default.
• W3192409202 hasConceptScore W3192409202C167135981 @default.
• W3192409202 hasConceptScore W3192409202C2776999253 @default.
• W3192409202 hasConceptScore W3192409202C2777658100 @default.
• W3192409202 hasConceptScore W3192409202C2777701055 @default.
• W3192409202 hasConceptScore W3192409202C2778715236 @default.
• W3192409202 hasConceptScore W3192409202C2781433595 @default.
• W3192409202 hasConceptScore W3192409202C2994587330 @default.
• W3192409202 hasConceptScore W3192409202C502942594 @default.
• W3192409202 hasConceptScore W3192409202C535046627 @default.
• W3192409202 hasConceptScore W3192409202C71924100 @default.
• W3192409202 hasConceptScore W3192409202C72563966 @default.
• W3192409202 hasConceptScore W3192409202C77350462 @default.
• W3192409202 hasIssue "8" @default.
• W3192409202 hasLocation W31924092021 @default.

• next